论文部分内容阅读
[目的]探讨非小细胞肺癌(NSCLC)患者血清periostin水平及其临床意义。[方法]采用酶联免疫吸附法(ELISA)检测102例NSCLC患者和40例良性肺部疾病患者血清periostin水平,并以35例健康人血清作为对照,比较不同分期、有无转移及术后1年复发与否的患者之间是否存在差异。[结果]NSCLC患者血清periostin水平[(38.6±18.7)ng/ml]显著高于健康对照者[(21.1±15.8)ng/ml,t=6.78,P<0.01]和良性肺部疾病者[(23.3±14.7)ng/ml,t=5.17,P<0.01]。Ⅲ/Ⅳ期患者血清periostin水平[(45.8±26.9)ng/ml]显著高于Ⅰ/Ⅱ期患者[(34.6±18.7)ng/mL,t=4.79,P<0.01]。有转移患者和术后1年内复发患者血清periostin水平分别高于无转移患者和无复发患者,差异均有统计学意义(t值分别为3.67,6.71,P<0.01)。[结论]NSCLC患者血清periostin水平有可能作为肿瘤转移和术后复发的预测指标。
[Objective] To investigate the serum periostin level in patients with non-small cell lung cancer (NSCLC) and its clinical significance. [Method] The serum periostin levels in 102 patients with NSCLC and 40 patients with benign lung disease were detected by enzyme-linked immunosorbent assay (ELISA). Serum levels of 35 healthy volunteers were compared with each other to compare the different stages, metastasis and postoperative 1 Year recurrence or not whether there is a difference between patients. [Results] The serum periostin level in NSCLC patients was significantly higher than that in healthy controls [(38.6 ± 18.7) ng / ml [(21.1 ± 15.8) ng / ml, t = 6.78, P <0.01] 23.3 ± 14.7) ng / ml, t = 5.17, P <0.01]. The level of periostin in patients with stage Ⅲ / Ⅳ [(45.8 ± 26.9) ng / ml] was significantly higher than that in stage Ⅰ / Ⅱ [(34.6 ± 18.7) ng / mL, t = 4.79, P <0.01]. The serum levels of periostin in patients with metastasis and recurrence within one year after surgery were significantly higher than those without metastasis and without recurrence (t = 3.67, 6.71, respectively, P <0.01). [Conclusion] The serum periostin level in patients with NSCLC may be used as predictors of tumor metastasis and postoperative recurrence.